Literature DB >> 23026929

Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers.

Stefano La Rosa1, Volkan Adsay, Luca Albarello, Sofia Asioli, Selenia Casnedi, Francesca Franzi, Alessandro Marando, Kenji Notohara, Fausto Sessa, Alessandro Vanoli, Lizhi Zhang, Carlo Capella.   

Abstract

Acinar cell carcinoma (ACC) of the pancreas is a very rare tumor that has various morphologic features, which may give rise to diagnostic difficulties. Because of its rarity, many clinicopathologic characteristics remain to be further elucidated, and prognostic factors are yet to be well established. With the aim of better characterizing this carcinoma and searching for prognostic indicators, we collected 62 ACCs and investigated the following parameters: site, size, local infiltration, node and distant metastases, architectural pattern, nuclear atypia, presence of necrosis, lymphovascular and perineural invasion, proliferation, BCL10, trypsin, carboxyl ester lipase, amylase, lipase, PDX1, cytokeratin 19 (CK19), CK7, p53, and β-catenin expression. Twelve cases showing >30% of endocrine cells were reclassified as mixed acinar-neuroendocrine carcinomas, whereas 1 tumor was reclassified as a mixed ductal-acinar carcinoma and was excluded from the statistical prognostic evaluations. BCL10 and trypsin were the most reliable immunohistochemical markers, whereas amylase and lipase were not. Surgery was statistically correlated with a better prognosis (P=0.0008). Among resected tumors there was no difference in survival between ACCs and mixed acinar-neuroendocrine carcinomas, and factors that significantly correlated with poor prognosis were size >6.5 cm (P=0.004), lymph node (P=0.0039) and distant (P=0.008) metastases, and UICC stage (P=0.009). Stage was the only independent prognostic factor at multivariable analysis, and the best prognostic discrimination was observed on grouping together stages I and II and grouping together stages III and IV, suggesting a simplification of the UICC staging for such cancers. In addition, vascular and perineural invasion and CK19 and p53 expression showed a trend for poor prognosis, not reaching statistical significance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23026929     DOI: 10.1097/PAS.0b013e318263209d

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  40 in total

Review 1.  [Classification and malignant potential of pancreatic cystic tumors].

Authors:  I Esposito; A M Schlitter; B Sipos; G Klöppel
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

2.  Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy.

Authors:  Emmet J Jordan; Olca Basturk; Jinru Shia; David S Klimstra; William Alago; Michael I D'Angelica; Ghassan K Abou-Alfa; Eileen M O'Reilly; Maeve A Lowery
Journal:  J Gastrointest Oncol       Date:  2017-10

Review 3.  Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms.

Authors:  Stefano La Rosa; Fausto Sessa; Silvia Uccella
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

Review 4.  Pathological and molecular evaluation of pancreatic neoplasms.

Authors:  Arvind Rishi; Michael Goggins; Laura D Wood; Ralph H Hruban
Journal:  Semin Oncol       Date:  2014-12-09       Impact factor: 4.929

5.  Intraductal Tubulopapillary Neoplasm of the Pancreas: A Clinicopathologic and Immunohistochemical Analysis of 33 Cases.

Authors:  Olca Basturk; Volkan Adsay; Gokce Askan; Deepti Dhall; Giuseppe Zamboni; Michio Shimizu; Karina Cymes; Fatima Carneiro; Serdar Balci; Carlie Sigel; Michelle D Reid; Irene Esposito; Helena Baldaia; Peter Allen; Günter Klöppel; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2017-03       Impact factor: 6.394

6.  Mixed acinar-endocrine carcinoma of the pancreas treated with S-1.

Authors:  Yusuke Kanemasa; Terumi Kamisawa; Taku Tabata; Sawako Kuruma; Susumu Iwasaki; Kazuro Chiba; Go Kuwata; Takashi Fujiwara; Hideto Egashira; Koichi Koizumi; Junko Fujiwara; Takeo Arakawa; Kumiko Momma; Hirofumi Rokutan; Shinichiro Horiguchi; Tsunekazu Hishima
Journal:  Clin J Gastroenterol       Date:  2013-09-05

7.  Clinics in diagnostic imaging (157). Acinar cell carcinoma (ACC) of the pancreatic tail.

Authors:  Marcus Jian Fu Ong; Yee Lin Tang; Cher Heng Tan
Journal:  Singapore Med J       Date:  2014-11       Impact factor: 1.858

8.  c-MYC amplification and c-myc protein expression in pancreatic acinar cell carcinomas. New insights into the molecular signature of these rare cancers.

Authors:  Stefano La Rosa; Barbara Bernasconi; Alessandro Vanoli; Amedeo Sciarra; Kenji Notohara; Luca Albarello; Selenia Casnedi; Paola Billo; Lizhi Zhang; Maria Grazia Tibiletti; Fausto Sessa
Journal:  Virchows Arch       Date:  2018-05-02       Impact factor: 4.064

9.  Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma.

Authors:  Stephan Kruger; Michael Haas; Philipp Johannes Burger; Steffen Ormanns; Dominik Paul Modest; Christoph Benedikt Westphalen; Axel Kleespies; Martin Kurt Angele; Werner Hartwig; Christiane Josephine Bruns; Thomas Kirchner; Jens Werner; Volker Heinemann; Stefan Boeck
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-14       Impact factor: 4.553

10.  Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.

Authors:  Yuchen Jiao; Raluca Yonescu; G Johan A Offerhaus; David S Klimstra; Anirban Maitra; James R Eshleman; James G Herman; Weijie Poh; Lorraine Pelosof; Christopher L Wolfgang; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos; Laura D Wood
Journal:  J Pathol       Date:  2014-03       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.